Azithromycin Versus Doxycycline on Restistin Level in Periodontitis Patients With Type 2 Diabetes

Phase 2CompletedNCT06199440

King Abdulaziz University15 enrolled

Overview

The aim of this study is to evaluate the adjunctive effects of systemic antibiotics used in nonsurgical periodontal treatment (NSPT), compared with NSPT alone, on the periodontal clinical parameters and resistin level in diabetic patients with periodontitis, in order to identify which, one provides an additional effect to non-surgical periodontal therapy

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

DIAGNOSTIC

Masking

SINGLE

Enrollment

Conditions

Periodontal Diseases Type 2 Diabetes

Interventions

Group IDRUG

First group are chronic periodontitis patients with diabetes mellitus type II who received scaling and root planning.

Group IIDRUG

Second group will receive 250 mg of azithromycin per day for a period of 5 days, after an initial dose of 500 mg one hour before NSPT.

Group IIIDRUG

Third group are Type 2 DM patients who received doxycycline 20mg twice/day. Gingival crevicular fluid will be collected at 0, 1, and 3 months to assess Serum Resistin using a human Resistin enzyme-linked immunosorbent assay Kit following the manufacturer's protocol.

Eligibility

Sex: ALLMin age: 25 YearsMax age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: Patients were clinically diagnosed as having at least three site with CAL ≥ 5mm; moderate to advanced chronic periodontitis according to the criteria of American Academy of Periodontology. * Free from any other systemic conditions that affect the periodontium except for Diabetes mellitus type II. * No periodontal therapy, systemic antibiotics or non-steroidal anti-inflammatory agents during the preceding 6 months. * Non-smokers. * Non-pregnant. Exclusion Criteria: \-

Locations (1)

King Abdulaziz University

Jeddah, Saudi Arabia

Outcomes

Primary Outcomes

Primary Outcome

Improvements in clinical parameters of periodontitis including Gingival Index, Probing Depth and Clinical Attachment Level

Time frame: 3 months

Secondary Outcomes

Secondary Outcome

Improved resistin level

Time frame: 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.